Resonance Health

Resonance Health EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Resonance Health (RHT.AX) as of Oct 24, 2026 is 258.86 %. In the previous year, Year-over-Year EBITDA Growth was -152.98 % — a change of -269.21% (higher).

EBITDA Growth YoY

258.86 %

YoY

-269.21%

Last updated:

Year-over-Year EBITDA Growth of Resonance Health is 2026 258.86 % . Year-over-Year EBITDA Growth of Resonance Health was 2025 -152.98 % . It decreases by -269.21% higher compared to the previous year.

The Resonance Health EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2019
1,473.07 AUD
Jan 1, 2020
-175.47 AUD
Jan 1, 2021
165.81 AUD
Jan 1, 2022
-343.11 AUD
Jan 1, 2023
11.50 AUD
Jan 1, 2024
67.94 AUD
Jan 1, 2025
-152.98 AUD
Jan 1, 2026
258.86 AUD
The Resonance Health EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
258.86 %-269.21%
-152.98 %-325.17%
67.94 %+490.74%
11.50 %-103.35%
-343.11 %-306.93%
165.81 %-194.49%
-175.47 %-111.91%
1,473.07 %+1,716.14%
81.11 %-126.24%
-309.16 %-46.97%
-582.95 %+561.28%
-88.15 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Resonance Health Stock analysis

What does Resonance Health do? Resonance Health Ltd is an Australian company that operates in the medical technology industry. The company's business model is to offer groundbreaking solutions for the diagnosis and treatment of liver and iron diseases. As a pioneering company in the development of methods and technologies for quantifying liver and iron concentrations, Resonance Health continually sets new standards in the industry. The company was founded in 2000 by a team of biomedicine professionals from the University of Western Australia. Over the years, the company has gained a lot of experience and constantly evolved to keep up with the progress of medical technology. The goal is to provide patients with better treatment and improved quality of life. One division of the company is the development and manufacturing of diagnostic tools for quantifying liver and iron diseases such as hepatitis, fatty liver, or hemochromatosis. The quantification method used by Resonance Health is called FerriScan. This method is non-invasive and painless, using magnetic resonance imaging (MRI) to measure the concentration of iron in the tissue. This is particularly important as a change in iron content can indicate a progressing liver disease. In addition to the FerriScan diagnostic tool, Resonance Health also offers a software package for analyzing FerriScan results, which is used by physicians and clinicians to assess disease progression. Furthermore, the company also develops solutions in the field of hemochromatosis, a genetic disorder that can lead to increased iron levels in the body. Another division of Resonance Health is the provision of research and development services to further develop and improve FerriScan and other technologies. The company collaborates with other companies, scientific institutions, and universities to advance the current developments in liver and iron diagnostics. Resonance Health has a range of products that contribute to better diagnosis and treatment of liver and iron diseases. These include FerriScan, the FerriSmart software package for precise monitoring of iron and liver health, and Hepatica, a software supporting hospitals and clinics in the diagnosis of liver diseases. The company is an innovative leader in the industry, contributing to improving the quality of life for patients. The products and services of Resonance Health have helped doctors and clinicians to effectively treat and diagnose liver and iron diseases. Additionally, the company has established a strong scientific foundation and works closely with leading institutions to continuously develop innovative solutions. Resonance Health is a company with a rich history that continues to evolve to meet the demands of the medical technology industry. The company aims to continuously improve the diagnosis and treatment of liver and iron diseases and offer better solutions. Resonance Health is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Resonance Health stock

Year-over-Year EBITDA Growth of Resonance Health is 258.86 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Resonance Health since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Resonance Health historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Resonance Health

All Key Metrics — Resonance Health